Rituximab may be an effective therapeutic option in the management of severe necrotizing scleritis associated with AAV. A middle-aged man was diagnosed with necrotizing scleritis associated with ...

Developing AAV capsids with improved yield, or fitness, is a key strategy for reducing manufacturing costs in order to make gene therapies more affordable. Christian Mueller and coauthors from ...

To assist researchers in the selection of the optimal AAV vector for their application, we have generated a detailed map of viral delivery to tissues in mice, the most commonly used experimental ...

This guide explores a faster, high-throughput approach to accurately evaluate AAV capsid content and help researchers improve efficiency and accelerate gene therapy development. Inside this technical ...

Gene therapy represents one of the fastest growing biotherapeutics worldwide, with AAV at the forefront. This rapid growth is constantly challenging CMC approaches, from manufacturing through release ...

An analysis of data on patients with AAV who underwent TPE found low short-term complication rates but an increased risk of serious infections. “The removal of autoantibodies and immune ...

This in silico approach aims to increase the fitness of clinical adeno-associated virus (AAV) capsids to make gene therapies more economically viable for patients. Developing AAV capsids with ...